Presentation

Intervacc is a Swedish company in animal health that develops safe, effective vaccines for animals. The company’s lead product Strangvac® is a vaccine based on fusions of recombinant proteins for equine strangles, a highly contagious infectious disease affecting horses globally. Strangvac® was approved by EMA in 2021. Nordvacc has a subsidiary, Nordvacc Läkemedel AB, which has been distributing high-quality veterinary products in the Nordic markets for 30 years. Intervacc also has a subsidiary lab Mybac-Vettech performing diagnostic services in veterinary bacteriology within the Swedish market.

Recent highlights
Net sales during Q1 amounted to SEK 1.2 million, which is on par with the same period 2021. In February, Intervacc announced the application for a Permit for Sale and Distribution of Strangvac® in the US. In March, Intervacc announced that the first batch of Strangvac® has been released for sale in Sweden. In May, the company further announced that Strangvac® has been released for sale in Denmark. Additionally, Intervacc announced positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with Streptococcus suis in April. The company also announced the initiation of a proof-of-concept study of a vaccine to protect dairy cows against mastitis caused by Staphylococcus aureus in May.

Outlook
The company looks forward to continuing the launch of Strangvac® in Europe following Sweden and Denmark. The company also aims to continue advancing its preclinical programs with ongoing studies.